Advanced Search

 

Study ID Status Title Patient Level Data
NKV110721 Completed A Study of Single Dose Intravenous Casopitant in Combination with Ondansetron and Dexamethasone for the Prevention of Oxaliplatin Induced Nausea and Vomiting.
NKV20001 Completed A Phase II Multicentre, Randomised, Double-Blind, Placebo and Active-Controlled, Dose-Ranging, Parallel Group Study of the Safety and Efficacy of the oral neurokinin-1 receptor antagonist, GW679769 When Administered at daily doses of 50 mg, 100 mg, and 150 mg Oral Tablets in Combination with Ondansetron Hydrochloride and Dexamethasone for the Prevention of Chemotherapy-Induced Nausea and Vomiting in Cancer Subjects Receiving Highly Emetogenic Cisplatin-based Chemotherapy.
NN210010 Completed A Phase I, Open Label, Randomized, Three Cohort Study to Investigate the Potential Pharmacokinetic Interaction, Safety and Tolerability of GW695634G 400mg q12h and Three Ritonavir-boosted HIV-1 Protease Inhibitors (Atazanavir, Fosamprenavir and Lopinavir) Following Oral Administration to Healthy ...
NOS103325 Completed A multicentre, two-part, randomised, double-blind, placebo-controlled, parallel-group study to evaluate the efficacy, tolerability and pharmacokinetics of the iNOS inhibitor GW274150 administered up to 120mg daily for 12 Weeks in the prophylactic treatment of migraine.
NPP30004 Completed A Multicenter, Double-blind, Randomized Study to Evaluate the Safety and Efficacy of Lamotrigine 200mg/day, 300mg/day, and 400mg/day Compared with Placebo in Subjects with Painful Diabetic Neuropathy Study Listed on ClinicalStudyDataRequest.com
NPP30005 Completed A Multicenter, Double-blind, Randomized Study to Evaluate the Safety and Efficacy of Lamotrigine 200mg/day, 300mg/day, and 400mg/day Compared with Placebo in Subjects with Painful Diabetic Neuropathy Study Listed on ClinicalStudyDataRequest.com
NPP30006 Completed Open label, safety study for use of lamictal in patients with diabetic neuropathy Study Listed on ClinicalStudyDataRequest.com
NPP30010 Completed A multicenter, randomized, double-blind, placebo-controlled, parallel group study to evaluate the safety and efficacy of lamotrigine in subjects with neuropathic pain and inadequate pain relief with gabapentin, tricyclic antidepressants or non-narcotic analgesics
NUC 30956 Completed AN OPEN STUDY OF LAMIVUDINE TREATMENT IN ADULT HBeAg NEGATIVE (presumed pre-core mutant) CHRONIC HEPATITIS B PATIENTS IN IRAN.
NUC105698 Completed A post-marketing surveillance to monitor the safety of Zeffix(Lamivudine) administered in Korean chronic hepatitis B virus infection subjects according to the prescribing information
NUC10901 Completed An Open Label Study of the Pharmacokinetics of Lamivudine (GR109714X) in Subjects Receiving Peritoneal Dialysis in Endstage Renal Failure Study Listed on ClinicalStudyDataRequest.com
NUC10902 Completed A randomized, open-label, cross-over study in Chinese healthy subjects, to establish bioequivalence between two formulations of Lamivudine (GR109714X) clinical trail material
NUC10905 Completed A randomised, open label, cross-over study in Chinese healthy subjects, to establish bioequivalence between lamivudine oral solution and tablet (GR109714X) clinical trial material.
NUC20904 Completed A randomised, stratified, double-blind, multicentre study of the safety and efficacy of 52 weeks treatment with adefovir dipivoxil and lamivudine for subjects with chronic hepatitis B who have developed hepatitis B virus variants and evidence of reduced therapeutic response to lamivudine
NUC20905 Completed A Multicentre, Double-blind, Randomised, Placebo-controlled Pilot Study to Evaluate the Effect of Lamivudine on Serum HDV RNA in Subjects Co-infected with Hepatitis B and Delta Virus Study Listed on ClinicalStudyDataRequest.com
NUC20912 Completed A Phase II Study of Lamivudine Compared to Lamivudine Plus Adefovir Dipivoxil for Subjects With Chronic Hepatitis B
NUC20917 Completed A double-blind, active-controlled, randomized 52-week extended follow-on study to investigate the long-term efficacy and safety of adefovir dipivoxil 10mg and lamivudine 100mg treatment for subjects with hepatitis B who have completed the previous Phase II protocol NUC20904
NUC20921 Completed Open-label compassionate access programme to provide adefovir dipivoxil and lamivudine to patients with Chronic Hepatitis B infection who are participating in or have completed, as appropriate, one of the following GlaxoSmithKline or Gilead Sciences Inc. clinical trials: NUC20917, NUC20912, NUCB4006, NUC40021
NUC30902 Completed A multicenter, prospective, descriptive study to compare the efficacy of lamivudine alone versus lamivudine plus anti-HB hyperimmune gammaglobulin in the prevention of hepatitis B virus reinfection after liver transplant.
NUC30903 Completed A Randomised, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of 52 Weeks Lamivudine Treatment at a Dose of 3 mg/kg in Paediatric Subjects with Chronic Hepatitis B
NUC30907 Completed A randomized, double-blind, placebo-controlled study of the treatment of HBsAg positive patients after stable renal transplantation with lamivudine
NUC30910 Completed Lamivudine for Prevention of HBV Reactivation in HBsAg Seropositive Patients undergoing Cytotoxic Chemotherapy
NUC30914 Completed A multicentre, randomised, double-blind, placebo-controlled study to evaluate the efficacy and tolerability of recombinant HBV vaccine and hepatitis B immunoglobulin (HBIg) plus lamivudine versus recombinant HBV vaccine and HBlg plus placebo for the prevention of mother-to-child transmission of HBV. Study Listed on ClinicalStudyDataRequest.com
NUC30919 Completed A double blind randomised multicentre study of lamivudine added to the current treatment in the therapy of chronic hepatitis B in HBV-DNA/anti-HBe positive Subjects.
NUC30925 Completed An open-label, Phase-IV study to demonstrate the efficacy and safety of locally manufactured (Suzhou, China) Lamivudine tablets (100mg) in Chinese patients with chronic hepatitis B (CHB)

 

 

For more information on this register please email GSKClinicalSupportHD@gsk.com

GSK-sponsored clinical studies are those for which GSK is ultimately responsible for all aspects of the study even if some or all of these activities are transferred to another party.
GSK-sponsored clinical trials are those for which GSK is ultimately responsible for all aspects of the study even if some or all of these activities are transferred to another party.

ClinicalTrial.gov is a database that provides summary protocol information for ongoing clinical trials.

IFPMA.org is a search portal provided by the International Federation of Pharamceutical Manufacturers & Associations (IFPMA).

This portal provides a single entry point to search for industry sponsored clinical trials which are on existing registers and databases.

EU Clinical Trials Register is a database of all clinical trials commencing in the European Community from 1 May 2004 onwards. It has been established in accordance with Directive 2001/20/EC.